Recently, Professor Long Xiao's team from Peking Union Medical College Hospital and Professor Zhou Zhou's team from Fuwai Hospital of the Chinese Academy of Medical Sciences collaborated to publish a research paper entitled "Single-cell RNA sequencing of subcutaneous adipose tissues identifies therapeutic targets for cancer-associated lymphedema" in the well-known journal Cell Discovery (impact factor: 38.101).
In this paper, the research team has revealed disease-related cell subpopulations, cell type specific regulatory changes, and intercellular communication changes in subcutaneous adipose tissue with lymphedema, and provided new targets for preventing or treating lymphedema.
This study is the first to conduct a single cell level study of adipose tissue derived from lymphedema, providing potential therapeutic targets and drugs for the clinical treatment of lymphedema.
Liu, X., Yuan, M., Xiang, Q. et al. Single-cell RNA sequencing of subcutaneous adipose tissues identifies therapeutic targets for cancer-associated lymphedema. Cell Discov 8, 58 (2022). https://doi.org/10.1038/s41421-022-00402-5
In this research work, a dodecapeptide, murine LR12 (LQEEDTGEYGCV; mLR12)57 was chemically synthesized by SBS Genetech. With almost 20 years of experience in solid-phase Peptide Synthesis, SBS Genetech is committed to supplying high-quality custom peptide(s) synthesis services at competitive prices and providing our customers with extensive services and products. SBS Genetech is also recognized as one of the global major leading industry players in Peptide Synthesis by third-party market researchers.
We are honored to create value for our customers and facilitate the development of science. At SBS Genetech, we firmly believe that by providing researchers with convenient and affordable research products, life sciences can benefit the world better.